Prognosis Prediction of CRAFITY Score in HCC Undergoing TACE Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapy.
Ze-Xin HuXiao-Yang XuZe WangJin-Tao HuangWan-Ci LiShuai ZhangJian ShenBin-Yan ZhongXiao-Li ZhuPublished in: Journal of hepatocellular carcinoma (2023)
The CRAFITY score may provide an efficient predictive capacity for prognosis in HCC patients undergoing TACE combined with PD-(L)1 inhibitors and molecular targeted therapy.
Keyphrases